The recognition that Bcl-2 promotes mitochondrial glycolysis to increase the survival of leukaemia stem cells led to the addition of a Bcl-2 inhibitor in the treatment regime for acute myeloid leukaemia [71]. Here, BCL2 is linked to acute myeloid leukemia.